Furthermore, certain cannabinoids like anandamide may reduce levodopa-induced dyskinesias by activating PPAR-γ, while the endogenous lipid ligand for PPAR-α, oleoylethanolamide, showed beneficial effects attributed to TRPV1 receptor blockade rather than PPAR-α activation [153,154]. Here, PPARA is linked to Dyskinesia.